CAMO 2026 – Cancer in Motion – brings together oncologists, researchers, clinicians, and healthcare professionals to explore advances in cancer biology, diagnosis, treatment, liquid biopsy, and precision oncology, fostering collaboration and innovation in cancer care. INTERNATIONAL SCIENTIFIC SYMPOSIUM Register Now View Agenda By Invite Only 24th October 2026, Saturday 9:30 AM to 3:00 PM IST (Indian Standard Time) Dr. Khanolkar Auditorium, ACTREC, Navi Mumbai Featuring the Launch of OncoDynamix™ Tumor-Informed Dual-Analyte Longitudinal Monitoring 2026 THEME From Circulating Tumor Cells to Dynamic Treatment Monitoring Register Now View Agenda Meet our speakers International Speakers Prof. Catherine Alix- Panabières Director, Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, France LinkedIn Prof. Klaus Pantel Director, Institute of Tumor Biology, University Medical Center, Hamburg-Eppendorf, Germany LinkedIn Prof. Catherine Alix-Panabières and Prof. Klaus Pantel jointly coined the term “Liquid Biopsy” in 2010, helping establish a new field of cancer research. Program Faculty Dr. T. Raja Director - Medical Oncology, Apollo Speciality Hospital, Chennai LinkedIn Program Director Dr. Pankaj Chaturvedi Director, ACTREC, Navi Mumbai LinkedIn Chief Guest Dr. J. N. Kulkarni Senior Consultant - Surgical Oncology, Bombay Hospital, Mumbai LinkedIn Chairperson Dr. Jayant Khandare Co-founder, MD & CSO, Actorius Innovations & Research LinkedIn Program Host Aravindan Vasudevan Co-founder & Director, Actorius Innovations & Research LinkedIn Program Host Dr. Kumar Prabhash Director, HBCHRC, Muzaffarpur LinkedIn Dr. K. Govind Babu Senior Medical Oncologist, HCG Cancer Hospital, Bengaluru LinkedIn Dr. Maheboob M. Basade HOD - Medical Oncology & Onco Surgery, Saifee Hospital, Mumbai LinkedIn Dr. Amit Joshi Professor & HOD - Medical Oncology, ACTREC, Navi Mumbai LinkedIn Dr. Bharat Bhosale Founder & Director, BB Precision OncoCare, Mumbai LinkedIn Dr. Nikhil Ghadyalpatil Director - Medical Oncology, Apollo Health City, Jubilee Hills, Hyderabad LinkedIn Dr. P. S. Dattatreya Chief Medical Oncologist & Clinical Director - Medical Oncology, KIMS Hospitals, Secunderabad LinkedIn Dr. Ankit Jain Senior Consultant - Medical Oncology, Indraprastha Apollo Hospitals, New Delhi LinkedIn Dr. Vindhya Vasini Senior Consultant - Medical Oncology, Omega Hospitals, Hyderabad LinkedIn Dr. Amol Kotalwar Senior Consultant - Medical & Hemato Oncology, Kotalwaar Superspeciality Clinic, Latur LinkedIn Dr. Sourav Mishra Associate Professor - Medical Oncology, AIIMS, Bhubaneswar LinkedIn Dr. Manish S. Bhandare Professor and Head of HPB and Upper GI unit, ACTREC, Navi Mumbai LinkedIn Dr. Aditya Dhanawat Assistant Professor - Medical Oncology, ACTREC, Navi Mumbai LinkedIn CAMO 2026 Agenda Download Agenda Morning Session Time Session/talk Speaker 9:30 - 10:00 AM Registration and Welcome Refreshments All Participants 10:00 - 10:05 AM Welcome and Opening Remarks Aravindan Vasudevan 10:05 - 10:10 AM Chief Guest Lecture Dr. Pankaj Chaturvedi 10:10 - 10:40 AM KEYNOTE I Liquid Biopsy in Precision Oncology: From Research to Clinical Practice Prof. Klaus Pantel 10:40 - 11:10 AM KEYNOTE II Liquid Biopsy: The Rise of a Medical Revolution Prof. Catherine Alix-Panabières 11:10 - 11:30 AM FIRESIDE CHAT I The Future of Liquid Biopsy A Conversation on the Breakthroughs, Opportunities, and Evolving Future Host: Dr. T.Raja Guests: Prof. Klaus Pantel Prof. Catherine Alix-Panabières 11:30 - 11:45 AM OncoDiscover® CTC Detection, Characterization and Clinical Experience Dr. Jayant Khandare 11:45 AM - 12:30 PM PANEL DISCUSSION I Bringing Liquid Biopsy into Routine Oncology Practice: Evidence, Opportunities and Challenges Moderator: Dr.Govind Babu 12:30 - 1:30 PM Networking Lunch Afternoon Session Time Session/talk Speaker 1:30 - 1:45 PM The Clinician’s Perspective What Do We Need from a Cancer Treatment Monitoring Test? Dr. Kumar Prabhash 1:45 - 2:00 PM Tumor-Informed Dual-Analyte Longitudinal Monitoring Test Concept, Workflow and Report Interpretation Dr. Jayant Khandare 2:00 - 2:15 PM FIRESIDE CHAT II Dual Analyte Monitoring: From Concept to Clinical Implementation Host: Dr.Bharat Bhosale Guest: Dr. Jayant Khandare 2:15 - 2:20 PM PRODUCT LAUNCH Formal Unveiling and Launch of new Test Unveiling Ceremony and Launch Photograph Chief Guest and other dignitaries 2:20 - 2:55 PM PANEL DISCUSSION II From Results to Decisions: Integrating CTCs and ctDNA into Clinical Practice Moderator: Dr. T.Raja 2:55 - 3:00 PM Closing Remarks, Faculty Appreciation and Vote of Thanks Aravindan Vasudevan Proposed agenda. Session titles and timings are subject to final faculty confirmation. Talk titles and panel participation remain subject to faculty approval. Scientific participation is separate from product validation or endorsement. This is a registration-only event. Please register here. Be a part of the conversation. Join leading clinicians, researchers, and healthcare experts for meaningful discussions shaping the future of oncology. CAMO 2026 is a invite-only event. Register your interest to receive an invitation to be part of this exclusive symposium. 24th October 2026, Saturday 9:30 AM – 3:00 PM, IST Indian Standard Time Dr. Khanolkar Auditorium, ACTREC, Navi Mumbai - 410210 Register your interest First name* Last name* Email* Phone* Company/Institute name* Position/Speciality* City and State* Country and Pincode* How would you be attending?* Offline Online I consent to my details being used to send me information and updates regarding CAMO 2026 . * Please note: This is an invite-only event . Registering your interest does not guarantee an invitation or a seat. Invitations will be extended based on seat availability. Attendance is confirmed only upon receipt of an official invitation. Register The Venue The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) is the state-of-the-art R&D wing of the Tata Memorial Centre, located in Kharghar, Navi Mumbai, at the foothills of the Sahyadri mountains. It comprises the Cancer Research Institute (CRI), Clinical Research Centre (CRC), and Centre for Cancer Epidemiology (CCE) , bringing together comprehensive expertise in cancer research, education, and care. The three centres work independently and collaboratively to advance cancer research, improve diagnosis, predict treatment outcomes, prolong survival, and ultimately contribute to better cancer care and cures. Know more about ACTREC Share your CAMO 2026 moments and conversations using #CAMO2026 LinkedIn X (Twitter) WhatsApp Copy link

Actorius Innovations and Research delivers regulatory-aligned cancer research solutions, enabling early detection, accurate monitoring, and impactful clinical decision support. Early is Everything. From breakthrough research to clinically meaningful diagnostics, Actorius is advancing innovations like OncoDiscover® that provide meaningful biological insights, helping clinicians make informed decisions and supporting patients throughout their cancer journey. Know More OncoDiscover® The OncoDiscover® CTC Test is India's first DCG(I) approved blood test that detects circulating tumor cells to reveal early cancer spread before it's visible. Book a test now Meet us at ISLB 2026 | November 7-9, 2026 | Madrid, Spain Featuring the Launch of OncoDynamix™ Tumor-Informed Dual-Analyte Longitudinal Monitoring From Circulating Tumor Cells to Dynamic Treatment Monitoring Register Now View Agenda About We are in pursuit of identifying and developing life-saving solutions for global healthcare problems with a focus on cancer diagnostics and cure. Trusted by: Why choose us? Our approach is grounded in rigorous research, advanced platforms, and a commitment to meaningful outcomes. 15000+ Patients Served 500+ Doctors Trust Us 100+ Publications 13+ Years of Excellence Accreditations/ Patents CDSCO Approved Test MD - 9; License No. MFG/IVD/2019/000031 NABL Accredited Lab Certificate No. NABLM0726MH08160 ISO Certified Lab ISO 13485:2016 by INTERTEK; Certificate No. 0140783 Globally Patented International Application No. PCT/IB2016/050779 Our Publications In collaboration with researchers and thought leaders around the world, Actorius Innovations' Team combines scientific expertise with cutting-edge innovation to advance the frontiers of cancer care. The research behind our products are supported by 100+ scientific publications presented at leading global forums such as ASCO, AACR, ESMO, ISLB, etc Read our publications Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. View all updates 1 Sept 2026 Longitudinal Assessment of Circulating Tumor Cells Expressing PD-L1 and Clusters in Esophageal Cancer Patients A longitudinal study of 110 esophageal cancer patients evaluated CTCs, PD-L1 expression, and CTC clusters, highlighting their potential as predictive biomarkers for treatment outcomes and occult minimal cellular residual disease. Know More 30 Aug 2026 Comparative Analysis of Circulating Tumor Cells, Clusters, and PD-L1 Expression in Paired Peripheral and Portal Venous Blood with Solid Malignancies A prospective study compares circulating tumor cells, CTC clusters, and PD-L1 expression in paired peripheral and portal venous blood, highlighting compartment-specific differences and the potential of dual-compartment liquid biopsy profiling. Know More 30 Aug 2026 Assessment of apprehension for Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre and Post Surgery Breast Cancer Patients A prospective study evaluates RUPIKA, a structured CTC-based MRD disclosure protocol, showing significantly reduced cancer worry among breast cancer patients after surgery compared with routine result communication. Know More Actorius in Action Stay updated with our latest events, scientific discussions, collaborations, and milestones that continue to shape the future of cancer research and innovation. View all events 7 Nov 2026 ISLB Annual Congress 2026 | 7-9 November | Madrid, Spain Actorius will present seven scientific posters at ISLB 2026 in Madrid, showcasing research advancing the clinical potential of CTCs across treatment monitoring, biomarker analysis, residual disease, and metastasis research. Read More 13 Sept 2026 Reflections from FHNO 2026 | Kashmir Reflections from FHNO 2026 in Kashmir, where Dr. Jayant Khandare engaged with leading Indian oncologists to exchange perspectives on cancer research, innovation, and the future of oncology. Read More 18 Aug 2026 14 Years of Actorius: A Journey of Innovation & Impact From circulating tumor cells and liquid biopsy to better cancer diagnostics —a journey driven by innovation, persistence, and the belief that better diagnostics can change lives. Read More © Copyright Actorius Innovations and Research In the News Explore how Actorius is making headlines in cancer research and diagnostics. View all mentions 29 Aug 2026 'कॅन्सर'ची टेस्ट शोधणाऱ्या मराठी माणसाचं आकाशाएवढं कर्तृत्व बघाच ! | डॉ.जयंत खंदारे. धाराशिवच्या डॉ. जयंत खंदारे यांनी अमेरिकेत संशोधन करून रक्तावरून कॅन्सरचे निदान करणारी जगातील केवळ दुसरी टेस्ट विकसित केली आहे. पुणे आणि अमेरिकेत त्यांच्या लॅब असून, कॅन्सर जनजागृतीसह त्यांच्या या महत्त्वपूर्ण शोधाच्या प्रेरणादायी प्रवासाचा घेतलेला हा वेध. Read More 24 May 2026 The Hidden Threat of a Single Cell: Dr. Jayant Khandare on How One Circulating Tumor Cell Can Restart the Cancer Journey The deadliest cancer threat may be invisible — just one surviving cell can be enough to restart the disease journey. Read More 17 Mar 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More FAQS Frequently Asked Questions Answers to commonly asked questions about Actorius and our offerings. Know More What makes Actorius different from conventional diagnostics companies? Actorius focuses on understanding cancer at the cellular level and translating that insight into precise, actionable outcomes. Our platforms are designed to look deeper, act earlier, and support more confident decisions. Who are Actorius’ solutions designed for? Our solutions are built for clinicians, researchers, healthcare partners, and institutions seeking advanced tools for cancer detection, analysis, and monitoring. How does Actorius approach precision oncology? We combine advanced biomaterials, biological insight, and data-driven analysis to study cancer behavior in detail—enabling earlier detection and more targeted intervention. Are Actorius’ technologies research-only or clinically applicable? Our work spans both research and translational applications. Some solutions are designed for research use, while others are developed with clinical deployment in mind, subject to regulatory requirements. How can I stay updated on Actorius’ work and developments? You can explore our latest blogs, newsletters, press releases, case studies, and events in the Resources section to stay informed about our progress and insights. Early detection is half the battle won. Empowering earlier insights so decisions can be made with confidence and care. Know More

Discover Actorius' journey. Learn how our innovation-driven, impact-obsessed start-up is revolutionizing early cancer detection. Our story so far An innovation-driven organisation 15000+ Patients Served 500+ Doctors Trust Us 100+ Publications 13+ Years of Excellence Innovation Driven Impact-obsessed Who we are About Actorius We innovate and create bio materials that have critical applications in the field of life sciences, drug delivery and medical diagnostics. We work with a vision to advance and improve human health. Trusted by: Mission, Vision & Purpose Innovating with Intent Our mission, vision, and purpose reflect our commitment to meaningful progress and measurable outcomes. Mission To develop innovative methodologies to develop diagnostic tests that provide early indicators of oncogenesis and enable informed treatment strategies. Vision To collectively advance and improve human health by developing biomedical innovations into practical applications that have wider reach, accessibility and affordability. Purpose To positively impact everyone, by developing solutions that have reduced time to decision making and providing precise information for a chosen course of action. Our Values What We Stand For Our values define our commitment to rigorous science, responsibility, and meaningful impact. Work on challenges with cutting-edge science and innovation. Work towards making it accessible and affordable to the masses. Ensure critical clinical validations for every outcome. Bio-materials with high specificity, efficiency and sensitivity. Scientific disciplines with interdisciplinary intelligence at the core. Take every little step to ensure cancer patient’s lives are saved. Accreditations/ Patents CDSCO Approved MD - 9; License No. MFG/IVD/2019/000031 NABL Accredited Lab Certificate No. NABLM0726MH08160 ISO certified ISO 13485:2016 by INTERTEK; Certificate No. 0140783 Globally Patented International Application No. PCT/IB2016/050779 Focused on creating novel cancer diagnostic tests. Know more Rigour in every action. Every product undergoes intense design and development. Leaving no stone unturned. We follow the most stringent quality norms like ISO13485 and NABL regulatory requirements. Passionate and emphatic. We are committed to developing solutions for unmet medical needs. We build high-risk innovative products, which have a very long life-cycle, using novel biomaterials. Licences License No: MFG / IVD2019 / 000004 License Name: MD 29 – Permission to import or manufacture new in-vitro diagnostic medical device. Licensing Authority: Central Drug Standards Control Organisation (CDSCO), New Delhi, India. License No: MFG / IVD2019 / 000031 License Name: MD 9 – License to Manufacture for Sale or for Distribution of Class C or Class D medical device. Licensing Authority: Central Drug Standards Control Organisation (CDSCO), New Delhi, India. ISO 13485:2016 Certified NABL Accredited Laboratory Detect cancer relapse early, when it can be cured. We are committed to bringing stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. India has a breakthrough in early cancer detection. Know More

Explore the latest resources from Actorius, a leading Oncology focused biotech company. Discover cutting-edge insights and innovations today! Resources Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. Patents Publications Events Press Release Expert Insights 7 Nov 2026 ISLB Annual Congress 2026 | 7-9 November | Madrid, Spain Actorius will present seven scientific posters at ISLB 2026 in Madrid, showcasing research advancing the clinical potential of CTCs across treatment monitoring, biomarker analysis, residual disease, and metastasis research. Read More 13 Sept 2026 Reflections from FHNO 2026 | Kashmir Reflections from FHNO 2026 in Kashmir, where Dr. Jayant Khandare engaged with leading Indian oncologists to exchange perspectives on cancer research, innovation, and the future of oncology. Read More 1 Sept 2026 Longitudinal Assessment of Circulating Tumor Cells Expressing PD-L1 and Clusters in Esophageal Cancer Patients A longitudinal study of 110 esophageal cancer patients evaluated CTCs, PD-L1 expression, and CTC clusters, highlighting their potential as predictive biomarkers for treatment outcomes and occult minimal cellular residual disease. Read More 30 Aug 2026 Comparative Analysis of Circulating Tumor Cells, Clusters, and PD-L1 Expression in Paired Peripheral and Portal Venous Blood with Solid Malignancies A prospective study compares circulating tumor cells, CTC clusters, and PD-L1 expression in paired peripheral and portal venous blood, highlighting compartment-specific differences and the potential of dual-compartment liquid biopsy profiling. Read More 30 Aug 2026 Assessment of apprehension for Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre and Post Surgery Breast Cancer Patients A prospective study evaluates RUPIKA, a structured CTC-based MRD disclosure protocol, showing significantly reduced cancer worry among breast cancer patients after surgery compared with routine result communication. Read More 30 Aug 2026 Algorithm based analysis of circulating tumour cells in cancer patients A study evaluating CellMatrics, a Python-based automated image analysis algorithm for CTC detection, demonstrated rapid and robust concordance with manual CTC analysis across blood samples from 32 cancer patients. Read More 30 Aug 2026 Detection of Androgen Receptor Splice Variant 7 in Circulating Tumor Cells for Dynamic Treatment Decision in Prostate Cancer Patients This study evaluated AR-V7 in CTCs and clusters from prostate cancer patients, highlighting its potential to predict ARSI resistance and support dynamic treatment decisions. Read More 30 Aug 2026 Capture of Cancerous Cells and Overall Survival in Rats using Ex-vivo Extracorporeal Device in Multiple Onco-dialysis Cycles An animal study evaluated OncoMetastat for ex-vivo cancer cell capture, safety, and survival in rats. Across multiple onco-dialysis cycles, cancer cells were captured, all test-group rats survived 14 days, and histopathology showed normal tissues. Read More 30 Aug 2026 Capture of Epithelial-Mesenchymal Transitioning Circulating Tumor Cells using Affinity Based N-Cadherin System A study demonstrating N-Cadherin affinity-based capture of EMT-associated CTCs in diverse cancers, with Vimentin-positive CTC detection in 90% of samples and N-Cadherin expression revealing heterogeneous metastatic phenotypes. Read More 30 Aug 2026 Evaluation of circulating tumor cells expressing PD-L1 and CTC clusters at baseline and follow ups in triple-negative breast cancer A retrospective study of 180 TNBC blood samples evaluated CTC burden, PD-L1 expression and CTC clusters using the CDSCO-approved OncoDiscover platform, highlighting their potential for longitudinal disease monitoring and biomarker-guided management. Read More 29 Aug 2026 'कॅन्सर'ची टेस्ट शोधणाऱ्या मराठी माणसाचं आकाशाएवढं कर्तृत्व बघाच ! | डॉ.जयंत खंदारे. धाराशिवच्या डॉ. जयंत खंदारे यांनी अमेरिकेत संशोधन करून रक्तावरून कॅन्सरचे निदान करणारी जगातील केवळ दुसरी टेस्ट विकसित केली आहे. पुणे आणि अमेरिकेत त्यांच्या लॅब असून, कॅन्सर जनजागृतीसह त्यांच्या या महत्त्वपूर्ण शोधाच्या प्रेरणादायी प्रवासाचा घेतलेला हा वेध. Read More 18 Aug 2026 14 Years of Actorius: A Journey of Innovation & Impact From circulating tumor cells and liquid biopsy to better cancer diagnostics —a journey driven by innovation, persistence, and the belief that better diagnostics can change lives. Read More 24 May 2026 The Hidden Threat of a Single Cell: Dr. Jayant Khandare on How One Circulating Tumor Cell Can Restart the Cancer Journey The deadliest cancer threat may be invisible — just one surviving cell can be enough to restart the disease journey. Read More 23 Apr 2026 AACR 2026 Highlights | April 17-22 | San Diego, California Highlights from AACR 2026 Read More 17 Mar 2026 ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Read More 17 Mar 2026 ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Read More 17 Mar 2026 ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. Read More 17 Mar 2026 AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. Read More 17 Mar 2026 ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. Read More 17 Mar 2026 AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Read More 17 Mar 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 14 Mar 2026 डॉ. जयंत खंदारे के नेतृत्व में एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड करेगी कैंसर की पहचान और मेटास्टेसिस नियंत्रण में नई क्रांतिकारी पहल एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड, एक अग्रणी भारत-अमेरिकी जैव-प्रौद्योगिकी कंपनी है जो आधुनिक सर्कुलेटिंग टयूमर सेल्स (CTC) तकनीकों के माध्यम से ऑन्कोलॉजी के क्षेत्र में परिवर्तन ला रही है। कंपनी के संस्थापक, प्रबंध निदेशक और मुख्य वैज्ञानिक अधिकारी डॉ. जयंत खंदारे के दूरदर्शी नेतृत्व में कंपनी यह उल्लेखनीय प्रगति कर रही है। Read More 14 Mar 2026 Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Read More 7 Mar 2026 AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. Read More 20 Feb 2026 Meeting with our International KOLs Our team meeting with oncology KOLs from the US and Europe. Read More 5 Feb 2026 Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Read More 27 Jan 2026 Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... Read More 3 Nov 2025 PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients This study demonstrates a high prevalence of CTCs in the endometrial cancer population. The presence of CTCs, CTC clusters, and PD-L1–overexpressing CTCs indicates occult minimal residual disease, disease aggressiveness, and potential progression toward metastasis. Read More 3 Nov 2025 Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. Read More 3 Nov 2025 Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Read More First Prev 1 Page 1 Next Last

The deadliest cancer threat may be invisible — just one surviving cell can be enough to restart the disease journey - Dr Jayant Khandare Press Release | 24 May 2026 The Hidden Threat of a Single Cell: Dr. Jayant Khandare on How One Circulating Tumor Cell Can Restart the Cancer Journey The deadliest cancer threat may be invisible — just one surviving cell can be enough to restart the disease journey. It takes just one cell to restart the story. In a thought-provoking insight into cancer progression, Dr. Jayant Khandare, Co-founder of Actorius Innovations and a leading researcher in circulating tumor cells, asks a pivotal question: “Can a single cell restart the cancer journey?” 🔗 Read the featured articles: English Article: https://english.dainikjagranmpcg.com/education/6a1285a923ea1/article-19162 Hindi Article: https://www.dainikjagranmpcg.com/national-international/the-hidden-danger-of-a-single-cell-dr-jayant-khandare/article-54101 Explore more research publications: https://www.actorius.in/newsroom #Actorius #DrJayantKhandare #CancerResearch #OncologyInnovation #LiquidBiopsy #OncoDiscover #CancerDiagnostics #HealthcareInnovation #PrecisionMedicine #CTC #CancerAwareness #MedicalResearch #Biotechnology #EarlyDetection #CancerCare Read Article Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover Lab Walkthrough Expert Insight | 9 August 2022 OncoDiscover Lab Walkthrough OncoDiscover Lab Walkthrough Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CaP-crowned CNT nanocapsules enable pH-triggered intracellular anticancer drug delivery. Publications | 17 April 2015 Manuscript:Calcium phosphate nanocapsule crowned multiwalled carbon nanotubes for pH triggered intracellular anticancer drug release Calcium phosphate–capped carbon nanotubes enable pH-triggered intracellular release of doxorubicin, preventing premature drug leakage and improving targeted cancer therapy. We report calcium phosphate (CaP) nanocapsule–crowned multiwalled carbon nanotubes (CNT–GSH–G4–CaP) as a novel platform for the intracellular delivery of an anticancer drug. As a proof of concept, the CNT–GSH–G4–CaP system demonstrates the release of the anticancer drug doxorubicin hydrochloride (DOX) within intracellular lysosomes from the interior cavity of the CNT through pH-triggered CaP dissolution. Importantly, we found that CNTs capped with a CaP nanolid can efficiently prevent premature drug release at physiological pH, while promoting DOX release in more acidic environments, such as those found in subcellular compartments like lysosomes (pH ≈ 5.0). This “zero premature release” characteristic is of significant clinical importance for delivering cytotoxic drugs, as it helps reduce systemic toxicity and enhances the effectiveness of anticancer treatment. We envision that this pH-triggered CaP-crowned CNT nanosystem could lead to a new generation of self-regulated platforms for the intracellular delivery of a wide range of anticancer drugs. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC-based PD-L1 and EGFR detection supports targeted therapy in lung cancer. Publications | 24 October 2023 ESMO 2023: Expression of PD-L1 and EGFR on circulating tumor cells in advanced Lung cancer patients CTC analysis using OncoDiscover® enables dynamic detection of PD-L1 and EGFR targets in advanced lung cancer, supporting personalized targeted and immunotherapy decisions. Background: Targeted molecular therapy and immunotherapy have revolutionized the treatment of advanced lung cancer (ALC). Although therapeutically significant, the outcome of immune checkpoint inhibitors (ICI) or tyrosine kinase inhibitors (TKI) depends on the presence of their respective targets in tumor cells. Evaluating targets based on solid tissue biopsy may often be misleading, particularly in progressive patients despite therapy administration. Additionally, tissue biopsy provides a static signature of target protein expression from an evolving tumor. The unmet need for dynamic detection and monitoring of actionable targets could be addressed by circulating tumor cells (CTCs). Here, we report on the utility of CTCs to detect actionable targets in advanced lung cancer (ALC) patients. Methods: We retrospectively analyzed 193 ALC patients for programmed death-ligand 1 (PD-L1) and EGFR expression on CTCs. CTCs were isolated using the Drug Controller General of India-approved OncoDiscover technology based on immunomagnetic targeting using anti-EpCAM antibodies and immunostaining with anti-EGFR and PD-L1 antibodies. CTCs were detected based on the expression of cytokeratins (CKs), absence of CD45, and prominent DAPI-stained nuclei. The presence or absence of EGFR and PD-L1 was determined using automated immunofluorescence microscopy. Results: Among the evaluated cohort, 67% of patients showed the presence of CTCs with a mean value of 4.2 (range: 1 to 62; SD = 10.65). The absence of CTCs in the remaining 33% of patients could be attributed to therapy response in clinically stable disease. Among all patients showing the presence of CTCs, 66% showed detectable expression of PD-L1, while 42% showed strong expression of EGFR. The presence of PD-L1 demonstrated a significant association with CTCs. Similarly, the expression of EGFR among detected CTCs showed high significance compared to reported tissue biopsy data in the literature. Conclusions: Detection of therapeutic targets on CTCs obtained from advanced lung cancer patients strongly indicates that these patients may qualify for anti-EGFR and PD-L1 targeted therapies. Systematic studies with larger sample sizes are required to further strengthen liquid biopsy–based detection of actionable targets. This approach could significantly benefit advanced lung cancer patients showing progressive disease despite chemotherapy or radiotherapy. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC counts correlate with nodal stage and aggressive features in Indian HNC patients. Publications | 7 March 2026 AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. Objectives To establish a rapid, highly specific, efficient, sensitive, and affordable CTC enumeration liquid biopsy technology and to validate its efficacy to isolate CTCs disseminating from epithelial tumors of the HNC subpopulation in India. Furthermore, the study aimed to investigate the correlation of CTC distribution from peripheral blood with respect to various clinicopathologic factors in these patients. Materials and Methods A cross-sectional study was conducted using peripheral blood from 350 enrolled HNC patients. CTCs were isolated using DCGI (India) approved technology that exploits EpCAM-based immunomagnetic separation. EpCAM+ tumor cells were isolated from only 1.5 ml of blood and critically assayed for cytokeratin 18 (CK18) expression. These cells were quantified using fluorescence imaging to obtain a threshold to further minimize nonspecific and false-positive enumeration. CTC enumeration was subsequently subjected to statistical correlation with various clinical and pathologic parameters. Results CTCs were detected in all HNC patients across various subsites. There was a minimum threshold of at least 12 CTCs in early oral cancer patients according to their clinicopathologic signatures. Compared to early oral cancer patients, advanced nodal patients showed a 40% escalation in CTC count, while an increase of up to 80% was observed when associated with aggressive features such as lymphovascular emboli (LVE) and extranodal extensions. Notably, laryngopharyngeal primary cases had the highest mean CTC count of 33 in 1.5 ml of blood. Conversely, patients with advanced disease had higher CTC counts, and this was staggered in comparison with nearly—but not all—clinical features. Remarkably, a higher clinical N (nodal) stage statistically correlated with increased CTC counts. A marked increase in CTCs was also seen in tumors that showed lymphovascular emboli on histopathology and extranodal extension. The CTC counts were independent of parameters such as age, sex, T stage, perineural invasion, bone involvement, or skin involvement. There was a notable trend toward reduced CTC counts after chemotherapy; however, it was not statistically significant. Conclusion This rapid and efficient CTC platform has been clinically validated for use in Indian HNC phenotypes. This is the first comprehensive study to show a staggering positive correlation between CTCs and various clinicopathologic factors, encompassing the largest number of oral cancer patients across the entire spectrum of HNSCC—the most common cancer in India. High CTC counts among HNC patients could possibly be one of the reasons for dismal outcomes, and further studies correlating CTCs with patient survival in HNC are warranted. However, this study strongly implicates the prospective utility of CTCs as a tumor marker in establishing clinical staging for HNC patients. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. Patents | 13 February 2023 Devices and methods for recovering disease-causing toxic constituents in the blood A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. The present disclosure relates to non-hemolytic blood compatible devices and methods for capture, enumeration, removal of disease-causing agents from the blood and for the treatment of the cancer patients. The said devices incorporating non-hemolytic compositions are useful for removing disease-causing agents 'ex vivo' from cancer patient's blood to prevent/delay the proliferation of cancer. The devices retain disease-causing agents in particular Circulating Tumor Cells (CTCs), allowing the passage of other blood constituents retaining the viability of hematopoietic cells. Related patent documents WO/2023/229674 CA3255372 IN202527040253 View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Discover our dynamic leadership team at Actorius Innovations. Join our leadership team to drive innovation and growth today! Our Dynamic Leadership Team Meet the team and learn about our mission. Dr. Jayant Khandare Cofounder, MD & CSO LinkedIn Aravindan Vasudevan Cofounder & Director LinkedIn Rick Kamble Cofounder & Director LinkedIn Want to be a part of this dynamic team? Visit our Careers section to explore current opportunities that match your interests and expertise. Apply Now

Self-propelled CNT microrockets enable rapid capture and isolation of CTCs. Publications | 13 April 2015 Manuscript: Self-propelled Carbon Nanotube Based Microrockets for Rapid Capture and Isolation of Circulating Tumor Cells Self-propelled CNT microrockets rapidly capture and magnetically isolate circulating tumor cells, enabling faster liquid biopsy and early cancer detection. We demonstrated a novel carbon nanotube (CNT)-based microrocket that propels efficiently through the thrust generated by oxygen (O₂) bubbles. These self-propelled microrockets exhibit ultrafast propulsion in aqueous solutions as well as in Dulbecco’s modified Eagle’s medium (DMEM). The microrocket generated a driving force of over 231 and 300 pN in DMEM containing 4% hydrogen peroxide (H₂O₂). The speed and distance traveled by the microrocket can be controlled by adjusting the concentration of H₂O₂. The designed multifunctional microrocket has the ability to (i) rapidly target (~5 minutes) and efficiently capture (~85%) transferrin receptor–positive (TfR⁺) cancer cells from an artificial CTC-like suspension, (ii) magnetically isolate the captured cells from peripheral blood cells, and (iii) enable subsequent high-resolution imaging. We envision that such self-powered micromotors could provide a novel and effective approach for the rapid and efficient extraction of circulating tumor cells (CTCs) from biological fluids, supporting early cancer diagnosis and detection of recurrence. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe